Literature DB >> 9393243

Incidence of gastrointestinal side effects due to alendronate is high in clinical practice.

R Kelly, H Taggart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9393243      PMCID： PMC2127746          DOI： 10.1136/bmj.315.7117.1235a

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

1.  Bisphosphonates and gastrointestinal damage.

Authors:  M A Blank; G W Gibson; R J Phipps; P N Smith
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

2.  Tolerability of alendronate. Comparison group taking placebo should have been included.

Authors:  M Kirby
Journal:  BMJ       Date:  1998-05-02

3.  Alendronate-induced unmasking or deterioration of coeliac disease: a case series.

Authors:  B G A Stuckey; R Sallie
Journal:  Osteoporos Int       Date:  2014-10-28       Impact factor: 4.507

4.  Pharmacovigilance study of alendronate in England.

Authors:  Pipasha N Biswas; Lynda V Wilton; Saad A W Shakir
Journal:  Osteoporos Int       Date:  2003-04-23       Impact factor: 4.507

5.  Tolerability and compliance with risedronate in clinical practice.

Authors:  B Hamilton; K McCoy; H Taggart
Journal:  Osteoporos Int       Date:  2003-04-10       Impact factor: 4.507

Review 6.  What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.

Authors:  David Y Graham
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

7.  Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females.

Authors:  Ji Oh Mok; Chan Hee Jung; Chul Hee Kim; Chang Beom Ryu; Yeo Joo Kim; Sang Jin Kim; Hyeong Kyu Park; Kyo Il Suh; Myung Hi Yoo; Dong-Won Byun
Journal:  Korean J Intern Med       Date:  2013-10-29       Impact factor: 2.884

8.  Persistence with teriparatide in patients with osteoporosis: the UK experience.

Authors:  N K Arden; S Earl; D J Fisher; C Cooper; S Carruthers; M Goater
Journal:  Osteoporos Int       Date:  2006-07-06       Impact factor: 4.507

9.  Treatment of ionized hypercalcemia in 12 cats (2006-2008) using PO-administered alendronate.

Authors:  B T Hardy; J F de Brito Galvao; T A Green; S R Braudaway; S P DiBartola; L Lord; D J Chew
Journal:  J Vet Intern Med       Date:  2015-01-12       Impact factor: 3.333
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.